Viracta Therapeutics, Inc.
HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES

Abstract:

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.